Cargando…

Structure of the core human NADPH oxidase NOX2

NOX2 is the prototypical member of the NADPH oxidase NOX superfamily and produces superoxide (O(2)(•−)), a key reactive oxygen species (ROS) that is essential in innate and adaptive immunity. Mutations that lead to deficiency in NOX2 activity correlate with increased susceptibility to bacterial and...

Descripción completa

Detalles Bibliográficos
Autores principales: Noreng, Sigrid, Ota, Naruhisa, Sun, Yonglian, Ho, Hoangdung, Johnson, Matthew, Arthur, Christopher P., Schneider, Kellen, Lehoux, Isabelle, Davies, Christopher W., Mortara, Kyle, Wong, Kit, Seshasayee, Dhaya, Masureel, Matthieu, Payandeh, Jian, Yi, Tangsheng, Koerber, James T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568551/
https://www.ncbi.nlm.nih.gov/pubmed/36241643
http://dx.doi.org/10.1038/s41467-022-33711-0
Descripción
Sumario:NOX2 is the prototypical member of the NADPH oxidase NOX superfamily and produces superoxide (O(2)(•−)), a key reactive oxygen species (ROS) that is essential in innate and adaptive immunity. Mutations that lead to deficiency in NOX2 activity correlate with increased susceptibility to bacterial and fungal infections, resulting in chronic granulomatous disease. The core of NOX2 is formed by a heterodimeric transmembrane complex composed of NOX2 (formerly gp91) and p22, but a detailed description of its structural architecture is lacking. Here, we present the structure of the human NOX2 core complex bound to a selective anti-NOX2 antibody fragment. The core complex reveals an intricate extracellular topology of NOX2, a four-transmembrane fold of the p22 subunit, and an extensive transmembrane interface which provides insights into NOX2 assembly and activation. Functional assays uncover an inhibitory activity of the 7G5 antibody mediated by internalization-dependent and internalization-independent mechanisms. Overall, our results provide insights into the NOX2 core complex architecture, disease-causing mutations, and potential avenues for selective NOX2 pharmacological modulation.